Ignite Synergy’s AI prescreening analyzes patient history, medications, and conditions to flag potential contraindications and safety considerations before sessions begin—helping teams standardize safety workflows.
AI prescreening integrated into psychedelic clinic workflows
Use screening outputs as decision support alongside protocol—especially when teams scale session volume.
Hubs: AI tools · Features · Contact
Trusted external resources
Independent research centers, directories, and clinical programs—provided for reference (Ignite Synergy is not affiliated unless explicitly stated).
- Lykos Therapeutics (formerly MAPS PBC) — Key sponsor of MDMA-assisted therapy trials.
- Erowid — Comprehensive, non-judgmental information on psychoactive substances.